RxDoctor Payments Data

Frank Han, MD

Pediatric Cardiology · Hartford, CTNPI 1801153952

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (58.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 79.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,738 and has fallen 97.8% since, to $38 in 2024.

$2,869in general payments, 2019–2025

Across 44 payments — averaging $65.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Pfizer$139
  • Novartis$108
  • BTG International Inc.$101
  • Abbott$91
  • Abiomed$50
  • plus $100 from 4 others

What the payments were for

  • Travel & lodging$1,67358%
  • Food & beverage$1,14640%
  • Education$502%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic18$2,280
Pfizer10$139
Novartis8$108
BTG International Inc.1$101
Abbott1$91
Abiomed1$50
Actelion Pharmaceuticals US, Inc.2$39
Astellas Pharma US Inc1$24
Braemar Manufacturing, LLC1$23
Irhythm Technologies, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,869 in reported general payments places this provider in the 75th percentile of 28 pediatric cardiology providers in Connecticut.

See all pediatric cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$1,063
Medicare patients
13
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$6,911
Metoprolol Succinate12$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$6,91112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 pediatric cardiology providers in Connecticut.

Other pediatric cardiology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →